Base de dados : MEDLINE
Pesquisa : C04.588.945.418 [Categoria DeCS]
Referências encontradas : 12100 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1210 ir para página                         

  1 / 12100 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29361624
[Au] Autor:Matsuoka N; Yokoyama T; Fujimoto E; Sakai M; Okame S; Shiroyama Y; Yokoyama T; Takehara K
[Ad] Endereço:Dept. of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center.
[Ti] Título:[Safety and Efficacy of Cisplatin Treatment after Carboplatin Hypersensitivity Reactions in Gynecologic Malignancies].
[So] Source:Gan To Kagaku Ryoho;44(13):2091-2095, 2017 Dec.
[Is] ISSN:0385-0684
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:To investigate the safety and efficacy of cisplatin(CDDP)treatment after carboplatin(CBDCA)hypersensitivity reactions (CHSR)in gynecologic malignancies, we retrospectively reviewed the clinical records of 544 patients who underwent paclitaxel and CBDCA therapy(TC therapy). CHSR was observed in 18 patients. Eight patients were administered weekly paclitaxel and CDDP therapy(wTP therapy)continuously, to confirm that there was no CDDP hypersensitivity followingintravenous administration of 10 mgCDDP. At the onset of CHSR, the patients had received a median of 9 TC therapy cycles, and the median number of CBDCA administrations was 14. The frequency of CHSR was significantly higher in patients who received 7 cycles or more of TC therapy and CBDCA administration(p<0.0001). The median number of wTP therapy administrations was 8. Although CDDP hypersensitivity reactions were observed in 2 patients, their symptoms were mild(Grade 2, CTCAE v4.0). Of the 6 patients who received wTP therapy and had evaluable disease sites, 1, 2, 2 and 1 patients showed CR, PR, SD, and PD, respectively. The median progression-free survival in these 6 patients was 9.5 months. For patients with the platinum- sensitive disease who have CHSR, CDDP could improve their prognosis.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Cisplatino/uso terapêutico
Hipersensibilidade a Drogas
Neoplasias dos Genitais Femininos/tratamento farmacológico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Antineoplásicos/efeitos adversos
Carboplatina/uso terapêutico
Cisplatino/efeitos adversos
Feminino
Seres Humanos
Meia-Idade
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); BG3F62OND5 (Carboplatin); Q20Q21Q62J (Cisplatin)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180302
[Lr] Data última revisão:
180302
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180124
[St] Status:MEDLINE


  2 / 12100 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29206956
[Au] Autor:Yaman S; Ayaz S
[Ad] Endereço:Nursing Department, Faculty of Health Sciences, Gazi University, Ankara, Turkey.
[Ti] Título:Psychological Problems Experienced by Women with Gynecological Cancer and How They Cope with It: A Phenomenological Study in Turkey.
[So] Source:Health Soc Work;41(3):173-181, 2016 Aug 01.
[Is] ISSN:0360-7283
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This study was carried out to reveal, in detail, the psychosocial problems faced by women in Turkey during their illness with gynecological cancer, and how they cope with these problems. The phenomenological approach used for the methodology is consistent with that described by Clark Moustakas's transcendental phenomenology. The sample included 17 married women. A semistructured, in-depth question directive was used to collect the data. The psychological problems found in the women in the study included frustration and despair, depression, inability to control anger, disruption in body image, and problems with their sex lives. The women in the study stated that, among other activities, they prayed frequently. They also emphasized that social support from family and others was important in coping. The majority said that they were able to cope through denial. Women under treatment for gynecological cancer should be evaluated from a psychosocial standpoint, and spiritual care and social support should be provided as they frequently use these to cope with their illness. It is recommended that a team be created, consisting of nurses, psychiatrists or psychologists, and religious staff to meet these needs.
[Mh] Termos MeSH primário: Adaptação Psicológica
Neoplasias dos Genitais Femininos/psicologia
[Mh] Termos MeSH secundário: Adulto
Imagem Corporal/psicologia
Depressão/psicologia
Emoções
Feminino
Seres Humanos
Entrevista Psicológica
Meia-Idade
Pesquisa Qualitativa
Sexualidade/psicologia
Apoio Social
Turquia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171206
[St] Status:MEDLINE
[do] DOI:10.1093/hsw/hlw030


  3 / 12100 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27776067
[Ti] Título:Practice Bulletin No. 174 Summary: Evaluation and Management of Adnexal Masses.
[So] Source:Obstet Gynecol;128(5):1193-1195, 2016 11.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Adnexal masses (ie, masses of the ovary, fallopian tube, or surrounding tissues) commonly are encountered by obstetrician-gynecologists and often present diagnostic and management dilemmas. Most adnexal masses are detected incidentally on physical examination or at the time of pelvic imaging. Less commonly, a mass may present with symptoms of acute or intermittent pain. Management decisions often are influenced by the age and family history of the patient. Although most adnexal masses are benign, the main goal of the diagnostic evaluation is to exclude malignancy. The purpose of this document is to provide guidelines for the evaluation and management of adnexal masses in adolescents, pregnant women, and nonpregnant women and to outline criteria for the identification of adnexal masses that are likely to be malignant and may warrant referral to or consultation with a gynecologic oncologist.
[Mh] Termos MeSH primário: Doenças dos Anexos
Neoplasias dos Genitais Femininos
[Mh] Termos MeSH secundário: Doenças dos Anexos/diagnóstico
Doenças dos Anexos/terapia
Adolescente
Feminino
Neoplasias dos Genitais Femininos/diagnóstico
Neoplasias dos Genitais Femininos/terapia
Seres Humanos
Gravidez
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE
[Em] Mês de entrada:1706
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  4 / 12100 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29183921
[Au] Autor:Kuhn E; Ayhan A
[Ad] Endereço:Pathology Unit, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy.
[Ti] Título:Diagnostic immunohistochemistry in gynaecological neoplasia: a brief survey of the most common scenarios.
[So] Source:J Clin Pathol;71(2):98-109, 2018 Feb.
[Is] ISSN:1472-4146
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Immunohistochemistry is a valuable adjunct in routine gynaecological pathology. The molecular revolution has redesigned knowledge of gynaecological cancers and refined histological classification. The direct consequence has been the progressive introduction of new immunostainings for diagnostic and classification purposes. Hence, we review the routine diagnostic use of immunohistochemistry in the field of gynaecological neoplasia. We reviewed the immunomarkers useful in gynaecological pathology according to literature revision, our personal experience and research findings. We discuss the application of immunohistochemistry to reach the most accurate diagnosis in morphologically equivocal cases of gynaecological pathology and present the appropriate panel of immunomarkers in the most common scenarios of gynaecological pathology. This short review provides an updated overview of the essential immunohistochemical markers currently used in the diagnostics of gynaecological malignancies along with their molecular rationale.
[Mh] Termos MeSH primário: Biomarcadores Tumorais/metabolismo
Carcinoma/diagnóstico
Neoplasias dos Genitais Femininos/diagnóstico
Imuno-Histoquímica
Leiomioma/diagnóstico
Sarcoma/diagnóstico
[Mh] Termos MeSH secundário: Carcinoma/metabolismo
Carcinoma/patologia
Diagnóstico Diferencial
Feminino
Neoplasias dos Genitais Femininos/metabolismo
Neoplasias dos Genitais Femininos/patologia
Seres Humanos
Leiomioma/metabolismo
Leiomioma/patologia
Gradação de Tumores
Estadiamento de Neoplasias
Sarcoma/metabolismo
Sarcoma/patologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Biomarkers, Tumor)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180202
[Lr] Data última revisão:
180202
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171130
[St] Status:MEDLINE
[do] DOI:10.1136/jclinpath-2017-204787


  5 / 12100 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29310324
[Au] Autor:Lee B; Kim K; Choi JY; Suh DH; No JH; Lee HY; Eom KY; Kim H; Hwang SI; Lee HJ; Kim YB
[Ad] Endereço:Department of Obstetrics and Gynecology, Hallym University Kangdong Sacred Heart Hospital, Gangdong-gu, Seoul.
[Ti] Título:Efficacy of the multidisciplinary tumor board conference in gynecologic oncology: A prospective study.
[So] Source:Medicine (Baltimore);96(48):e8089, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Evidence has shown that multidisciplinary tumor board conferences (MTBCs) improve patient management for various cancer types. However, few retrospective studies have investigated MTBC efficacy for patients with gynecologic cancers. Here, we prospectively aimed to evaluate how MTBCs influence patient management in gynecologic oncology. This prospective study included 85 consecutive cases that were presented at gynecologic oncology MTBCs in our tertiary university hospital between January 2015 and April 2016. The primary endpoint was treatment plan change rate, which included both major and minor changes. Major changes were defined as exchange, addition, or subtraction of treatment modality. Minor changes included all other, such as intramodality changes or treatment time changes. The secondary endpoints were the change rates of diagnosis, diagnostic work-up, and radiological and pathological findings.The treatment plan change rate, irrespective of changes in diagnostic work-up, was 27.1%, which included 10.6% major and 16.5% minor changes. Among the treatment plan changes, changes in the treatment plan change rate alone were noted in 16.5% of cases, and changes in diagnosis and radiological findings occurred in 7.1% and 3.5% of cases, respectively. Diagnosis and radiological findings, irrespective of changes in diagnostic work-up, were also changed in 9.4% and 10.6% of cases, respectively. However, there were no changes in pathological findings. Moreover, there was a change of diagnostic method for further work-up in 23.5% of cases. The implementation rate of MTBC-determined treatment changes was 91.8%. Gynecologic oncology MTBCs resulted in considerable changes in treatment plans. Diagnosis, diagnostic work-up, and radiological findings were influenced by MTBCs. The data emphasize the importance of adopting a multidisciplinary team approach for gynecologic cancer management.
[Mh] Termos MeSH primário: Neoplasias dos Genitais Femininos/terapia
Comunicação Interdisciplinar
Oncologia
Planejamento de Assistência ao Paciente
Equipe de Assistência ao Paciente
[Mh] Termos MeSH secundário: Diagnóstico por Imagem
Feminino
Neoplasias dos Genitais Femininos/diagnóstico
Seres Humanos
Meia-Idade
Estudos Prospectivos
República da Coreia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180115
[Lr] Data última revisão:
180115
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008089


  6 / 12100 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29266071
[Ti] Título:ACOG Committee Opinion No. 727 Summary: Cascade Testing: Testing Women For Known Hereditary Genetic Mutations Associated With Cancer.
[So] Source:Obstet Gynecol;131(1):194-195, 2018 Jan.
[Is] ISSN:1873-233X
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:"Cascade testing" refers to the performance of genetic counseling and testing in blood relatives of individuals who have been identified with specific genetic mutations. Testing protocols and other interventions may save lives and improve health and quality of life for these family members. Obstetrician-gynecologists should know who is eligible for cascade testing and should use all available resources to ensure that cascade testing is offered and occurs in a timely manner. Despite the clear health benefits for specific populations and individuals, obstetrician-gynecologists should be aware of the potential barriers to cascade testing and should know which options can help patients overcome those barriers. Such barriers, however, may be overcome with health care provider awareness and participation in local and state initiatives to improve implementation of cascade testing. Resources (available within federal and state agencies, professional societies, and in advocacy and community groups) are critical to the successful implementation of cascade testing. This Committee Opinion focuses specifically on cascade testing and the role of the obstetrician-gynecologist in clinical and public health efforts to increase identification of women with hereditary cancer syndromes.
[Mh] Termos MeSH primário: Predisposição Genética para Doença/prevenção & controle
Testes Genéticos/métodos
Neoplasias dos Genitais Femininos/genética
Síndromes Neoplásicas Hereditárias/diagnóstico
Síndromes Neoplásicas Hereditárias/genética
Guias de Prática Clínica como Assunto
[Mh] Termos MeSH secundário: Comitês Consultivos
Medicina Baseada em Evidências
Feminino
Aconselhamento Genético/organização & administração
Neoplasias dos Genitais Femininos/prevenção & controle
Seres Humanos
Programas de Rastreamento/métodos
Mutação/genética
Gravidez
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180108
[Lr] Data última revisão:
180108
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE
[do] DOI:10.1097/AOG.0000000000002451


  7 / 12100 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28743274
[Au] Autor:Kuroda K; Yamamoto Y; Yanagisawa M; Kawata A; Akiba N; Suzuki K; Naritaka K
[Ad] Endereço:Department of Obstetrics and Gynecology, Yaizu City Hospital, 1000, Dobara, Yaizu-shi, 425-8505, Japan. kenji.kuroda@hospital.yaizu.shizuoka.jp.
[Ti] Título:Risk factors and a prediction model for lower limb lymphedema following lymphadenectomy in gynecologic cancer: a hospital-based retrospective cohort study.
[So] Source:BMC Womens Health;17(1):50, 2017 07 25.
[Is] ISSN:1472-6874
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Lower limb lymphedema (LLL) is a chronic and incapacitating condition afflicting patients who undergo lymphadenectomy for gynecologic cancer. This study aimed to identify risk factors for LLL and to develop a prediction model for its occurrence. METHODS: Pelvic lymphadenectomy (PLA) with or without para-aortic lymphadenectomy (PALA) was performed on 366 patients with gynecologic malignancies at Yaizu City Hospital between April 2002 and July 2014; we retrospectively analyzed 264 eligible patients. The intervals between surgery and diagnosis of LLL were calculated; the prevalence and risk factors were evaluated using the Kaplan-Meier and Cox proportional hazards methods. We developed a prediction model with which patients were scored and classified as low-risk or high-risk. RESULTS: The cumulative incidence of LLL was 23.1% at 1 year, 32.8% at 3 years, and 47.7% at 10 years post-surgery. LLL developed after a median 13.5 months. Using regression analysis, body mass index (BMI) ≥25 kg/m (hazard ratio [HR], 1.616; 95% confidence interval [CI], 1.030-2.535), PLA + PALA (HR, 2.323; 95% CI, 1.126-4.794), postoperative radiation therapy (HR, 2.469; 95% CI, 1.148-5.310), and lymphocyst formation (HR, 1.718; 95% CI, 1.120-2.635) were found to be independently associated with LLL; age, type of cancer, number of lymph nodes, retroperitoneal suture, chemotherapy, lymph node metastasis, herbal medicine, self-management education, or infection were not associated with LLL. The predictive score was based on the 4 associated variables; patients were classified as high-risk (scores 3-6) and low-risk (scores 0-2). LLL incidence was significantly greater in the high-risk group than in the low-risk group (HR, 2.19; 95% CI, 1.440-3.324). The cumulative incidence at 5 years was 52.1% [95% CI, 42.9-62.1%] for the high-risk group and 28.9% [95% CI, 21.1-38.7%] for the low-risk group. The area under the receiver operator characteristics curve for the prediction model was 0.631 at 1 year, 0.632 at 3 years, 0.640 at 5 years, and 0.637 at 10 years. CONCLUSION: BMI ≥25 kg/m , PLA + PALA, lymphocyst formation, and postoperative radiation therapy are significant predictive factors for LLL. Our prediction model may be useful for identifying patients at risk of LLL following lymphadenectomy. Providing an intensive therapeutic strategy for high-risk patients may help reduce the incidence of LLL and conserve the quality of life.
[Mh] Termos MeSH primário: Neoplasias dos Genitais Femininos/cirurgia
Excisão de Linfonodo/efeitos adversos
Linfedema/etiologia
Modelos Teóricos
Complicações Pós-Operatórias/etiologia
[Mh] Termos MeSH secundário: Adulto
Idoso
Área Sob a Curva
Feminino
Neoplasias dos Genitais Femininos/patologia
Hospitais/estatística & dados numéricos
Seres Humanos
Incidência
Estimativa de Kaplan-Meier
Extremidade Inferior/patologia
Excisão de Linfonodo/métodos
Linfonodos/patologia
Linfedema/epidemiologia
Linfedema/patologia
Meia-Idade
Prevalência
Modelos de Riscos Proporcionais
Estudos Retrospectivos
Medição de Risco/métodos
Fatores de Risco
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171226
[Lr] Data última revisão:
171226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170727
[St] Status:MEDLINE
[do] DOI:10.1186/s12905-017-0403-1


  8 / 12100 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29187500
[Au] Autor:Lee HJ; Lee YH; Chong GO; Hong DG; Lee YS
[Ad] Endereço:Department of Obstetrics and Gynecology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
[Ti] Título:Robotic-assisted Transperitoneal Infrarenal Para-aortic Lymphadenectomy for Gynecological Malignancies: Comparison with a Laparoscopic Approach.
[So] Source:Anticancer Res;37(12):7087-7093, 2017 12.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: We evaluated the clinical feasibility and surgical outcomes of robotic-assisted transperitoneal infrarenal para-aortic lymphadenectomy (TIPAL) in patients with gynecological malignancies. PATIENTS AND METHODS: The perioperative outcomes in 90 patients with gynecological malignancies who underwent laparoscopic (n=43) or robotic-assisted (n=47) TIPAL were compared retrospectively. RESULTS: The operative time for pelvic and total lymphadenectomy were significantly shorter in the robotic-assisted approach, whereas the time for infrarenal para-aortic lymphadenectomy did not differ statistically. In contrast, the number of infrarenal para-aortic lymph nodes was significantly higher in the robotic-assisted approach. We compared the time per retrieved lymph node in both approaches, and those for pelvic, infrarenal para-aortic, and total lymphadenectomy were significantly shorter in the robotic-assisted approach. CONCLUSION: In our study, the robotic-assisted TIPAL took less time to retrieve a lymph node than the laparoscopic approach. The robotic-assisted approach for TIPAL is feasible for the staging and treatment of patients with gynecological malignancies.
[Mh] Termos MeSH primário: Neoplasias dos Genitais Femininos/cirurgia
Laparoscopia/métodos
Excisão de Linfonodo/métodos
Procedimentos Cirúrgicos Robóticos/métodos
[Mh] Termos MeSH secundário: Adulto
Estudos de Viabilidade
Feminino
Seres Humanos
Linfonodos
Metástase Linfática
Meia-Idade
Estudos Retrospectivos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171211
[Lr] Data última revisão:
171211
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE


  9 / 12100 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29187471
[Au] Autor:Tinelli G; Cappuccio S; Parente E; Fagotti A; Gallotta V; Conte C; Costantini B; Gueli Alletti S; Scambia G; Vizzielli G
[Ad] Endereço:Division of Vascular Surgery, "Agostino Gemelli" Foundation University Hospital, Catholic University, Rome, Italy.
[Ti] Título:Resectability and Vascular Management of Retroperitoneal Gynecological Malignancies: A Large Single-institution Case-Series.
[So] Source:Anticancer Res;37(12):6899-6906, 2017 12.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: To report on morbidity and oncological outcomes in a consecutive series of gynecological malignancies involving the vascular district. PATIENTS AND METHODS: We retrospectively evaluated a consecutive series between 1/2015 and 1/2017 with suspicious gynecological malignancies involving the vascular district. Peri-operative data and survival rates were computed. RESULTS: Eight-hundred-four women with gynecological malignancies were admitted for major oncologic surgery during the study period, and among them, 50 cases (6.2%) showed vascular involvement. Twenty-seven and 23 patients were submitted to minor and major vascular procedures, respectively. R0 resection was achieved in 44 patients. There were no perioperative mortalities. Major postoperative complications occurred in 6 patients (12.0%). The 2-year disease free survival (DFS) was 67% if R0 resection was achieved. In patients with positive pathological margins (n=2), the 2-year DFS was 33%. CONCLUSION: Vascular procedures can be safely performed with a proper pre-operative planning and may not be an impediment to major gynecological oncological surgery.
[Mh] Termos MeSH primário: Neoplasias dos Genitais Femininos/cirurgia
Complicações Pós-Operatórias/diagnóstico
Neoplasias Retroperitoneais/cirurgia
Procedimentos Cirúrgicos Vasculares/métodos
[Mh] Termos MeSH secundário: Abscesso/diagnóstico
Abscesso/etiologia
Adulto
Idoso
Feminino
Neoplasias dos Genitais Femininos/irrigação sanguínea
Seres Humanos
Estimativa de Kaplan-Meier
Meia-Idade
Infecção Pélvica/diagnóstico
Infecção Pélvica/etiologia
Complicações Pós-Operatórias/etiologia
Neoplasias Retroperitoneais/irrigação sanguínea
Estudos Retrospectivos
Procedimentos Cirúrgicos Vasculares/efeitos adversos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171211
[Lr] Data última revisão:
171211
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE


  10 / 12100 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:29061774
[Au] Autor:Gadducci A; Guerrieri ME
[Ad] Endereço:Department of Experimental and Clinical Medicine, Division of Gynecology and Obstetrics University of Pisa, Pisa, Italy a.gadducci@med.unipi.it.
[Ti] Título:Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research.
[So] Source:Anticancer Res;37(11):5955-5965, 2017 11.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:The presence of tumor infiltrating lymphocytes (TILs) influences the clinical outcome of cancer patients and immune checkpoint inhibitors (ICPI) have been approved for treating different types of malignancies. In this review, we assess the scanty data from literature and the perspectives of clinical research about the use of ICPI in gynecological cancers. These agents have obtained objective response rates ranging from 5.9% to 15% in early phase Ib-II trials, including patients with platinum-resistant ovarian cancer, whereas only anecdotal data are available for patients with recurrent, heavily pretreated endometrial cancer. Several ongoing trials are investigating ICPI alone or in combination with chemotherapy or with other biological agents in untreated and recurrent ovarian cancer, advanced and recurrent endometrial cancer, as well as advanced and recurrent cervical cancer. Breast cancer (BRCA)-mutated high-grade serous ovarian cancers, clear cell ovarian cancers with microsatellite instability (MSI), POLE ultramutated and MSI hypermutated endometrial cancers are likely to be sensitive to programmed cell death (PD-1)/PD-ligand 1 (PD-L1) pathway blockade, since these tumors show increased neoantigen load, increased CD8 TIL number and PD-1 and PD-L1 overexpression. ICPI could have a role as maintenance treatment in patients with persistent, recurrent or metastatic cervical cancer in response after chemotherapy.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Pontos de Checagem do Ciclo Celular/efeitos dos fármacos
Neoplasias dos Genitais Femininos/tratamento farmacológico
Neoplasias dos Genitais Femininos/imunologia
Imunoterapia
[Mh] Termos MeSH secundário: Animais
Feminino
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Antineoplastic Agents)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171025
[St] Status:MEDLINE



página 1 de 1210 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde